Skip to content

Laparoscopic Versus Open PANP-TME for Male Mid-low Rectal Cancer Patients

Comparisons of Urinary and Sexual Function Protection and Long-term Outcomes Between Laparoscopy-assisted and Open Pelvic Autonomic Nerve Preservation Total Mesorectum Excision for Male Mid-low Rectal Cancer Patients: a Randomized Controlled Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02164136
Enrollment
172
Registered
2014-06-16
Start date
2014-06-30
Completion date
2023-06-30
Last updated
2018-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectum Neoplasms

Brief summary

TME (Total mesorectum excision) is the golden standard of radical resection for mid-low rectal cancer. However, the damage of pelvic autonomic nerve following with TME principle will lead to high incidence of urinary and sexual function disorder. Open PANP (pelvic autonomic nerve preservation) TME surgery played a role in decreasing incidence of urinary and sexual function disorder. However, 32%-44% patients still suffered from urinary and sexual function disorder when underwent Open PANP TME surgery (O-PANP-TME). Laparoscopy-assisted TME surgery (L-TME) is applied wildly nowadays. In the early stage of work, we performed laparoscopy-assisted PANP TME surgery (L-PANP-TME) to discuss the protection of urinary and sexual function of male mid-low rectal cancer patients. The results showed that L-PANP-TME significantly decreased incidence of urinary and sexual function disorder. In order to further confirm our early work, we design a randomized controlled clinical trial to compare differences in urinary and sexual function protection and long-term outcomes between L-PANP-TME and O-PANP-TME.

Interventions

PROCEDUREL-PANP-TME
PROCEDUREO-PANP-TME

Sponsors

Third Affiliated Hospital, Sun Yat-Sen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
20 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Age from over 20 to under 60 years; * Primary rectal adenocarcinoma confirmed pathologically by endoscopic biopsy; * Mid-low rectal cancer (distance from anal edge≤12cm); * cT1-3, N0-3, M0 at preoperative evaluation according to the AJCC Cancer Staging Manual Seventh Edition; * Expected curative resection through both L-PANP-TME and O-PANP-TME; * Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group) scale; * ASA (American Society of Anesthesiology) score class I, II, or III; * Written informed consent; * Urinary and sexual function normal preoperatively

Exclusion criteria

* Women during pregnancy or breast-feeding; * Severe mental disorder; * History of previous pelvic surgery; * Enlarged or bulky regional lymph node diameter over 3cm by preoperative imaging; * History of other malignant disease within past five years; * History of unstable angina or myocardial infarction within past six months; * History of cerebrovascular accident within past six months; * History of continuous systematic administration of corticosteroids within one month; * Contraindication of heart, brain, lung, etc dysfunction; * Requirement of simultaneous surgery for other disease; * Emergency surgery due to complication (bleeding, obstruction or perforation) caused by rectal cancer; * Rectal cancer invades surrounding tissues; * Existence of genuine incontinence or severe stress incontinence preoperatively

Design outcomes

Primary

MeasureTime frameDescription
3-year disease free survival rate36 months
Urinary function30 daysUrodynamic study and IPSS (International prostate symptom score) are used to assess urinary function
Sexual function30 daysIIEF-5 (International questionnaire of erectile function-5) and Ejaculation function classification are used to assess sexual function
5-year disease free survival rate60 months

Secondary

MeasureTime frame
5-year overall survival rate60 months
Morbidity30 days
5-year recurrence pattern60 months
3-year overall survival rate36 months
3-year recurrence pattern36 months
Mortality30 days

Countries

China

Contacts

Primary ContactHongbo Wei, M.D. Ph.D.
drweihb@126.com+86-189-2210-2969

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026